



# Steroids with and Without Antivirals in the Treatment of Bell's Palsy: Does It Make any Difference in Recovery? A Study at a Tertiary Care Center, Karachi, Pakistan

Abu Talib<sup>1</sup>, Gohar Baloch<sup>1</sup>, Iftikhar Haider Naqvi<sup>1</sup> and Muhammad Ubaid<sup>1,\*</sup>

<sup>1</sup>Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan

\*Corresponding author: Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan. Email: muhammad.ubaid@duhs.edu.pk

Received 2021 April 27; Revised 2021 August 10; Accepted 2021 August 15.

## Abstract

**Objectives:** To compare the pharmacological effects of steroids in comparison to steroids with antiviral drugs for the treatment of Bell's Palsy.

**Methods:** A total 60 patients were enrolled and segregated equally into two groups, where patients on prednisolone were labeled as group A (Control group), whereas patients on prednisolone + acyclovir were labeled as group B (study group). All patients had House Brackmann score. The control group started oral prednisolone 1 mg/kg for 10 days, whereas the study group started acyclovir 400 mg 4 times a day for 10 days along with prednisolone tablets. Patients were regularly observed till the study was completed. Primary outcome measure was facial nerve recovery. Health-related quality of life and facial appearance were considered secondary outcomes.

**Results:** The primary outcomes assessed as complete recovery from Bell's Palsy by Brackmann score at week 4 were found in 17/30 (57%) patients and 23/30 (77%) patients at week 8 in the control group. Complete recovery from Bell's Palsy was also shown in the experimental group (Prednisolone + acyclovir) where 25/30 (83%) patients completed recovery at week 4, while 27/30 (90%) patients at week 8. Comparison of the two groups showed a significant improvement in the study group (prednisolone + acyclovir) ( $P = 0.047$ ) at week 4 and ( $P = 0.02$ ) at week 8. The secondary outcomes were assessed as improvement in the quality of life and facial appearance from Bell's Palsy. Health utility score was  $0.84 \pm 0.01$  in the control group (On prednisolone) with facial appearance score of (Derriford appearance scale 59)  $61 \pm 28$ . At week 4, the study group (on prednisolone+ acyclovir) showed  $0.88 \pm 0.12$  score on Health utility index scale-3 and  $46 \pm 26$  score on Derriford appearance scale. Comparison of the quality of life (Health quality index scale-3) and facial appearance among both control and study groups showed a significant improvement in the study group ( $P = 0.001$  and  $P = 0.005$ , respectively). Moreover, when health utility score and Derriford appearance were compared among both groups, it showed a significant improvement in the study group ( $P = 0.001$  and  $0.016$ , respectively).

**Conclusions:** The combination of prednisolone with acyclovir is found superior to prednisolone alone, and this combination treatment results in improvement in both recovery and quality of life.

**Keywords:** Bell's Palsy, Derriford Appearance Scale, Acyclovir, Prednisolone

## 1. Background

Human's face is a focal point for expression, and communication with its proper function has a great impact on human's quality of life. Facial nerve dysfunction, causing facial disturbance with both cosmetic and functional components, can severely hamper patients' quality of life. Facial nerve palsy may occur with trauma, iatrogenic, stroke, and idiopathic Bell's Palsy. Other known causes are multiple sclerosis, malignancy, and meningitis related to granulomatous diseases. Central and peripheral facial weakness requires a complete neurological history and thor-

ough physical examination. The most frequent causative factor for facial nerve paralysis is Bell's Palsy or Antoni's Palsy. The incidence of this palsy has been reported (20-30/100,000/annum) with equal gender involvement (1). In the majority (60 - 75%) of patients having unilateral facial paralysis, the underlying etiology is Bell's Palsy (2). The median age of the presentation of Bell's Palsy is 40 years. However, this can occur at any age (3). Both sides of the face are equally involved by the Bell's Palsy (3).

The possible proposed pathogenetic explanation for Bell's Palsy is inflammation of VII cranial nerve at sensory ganglion, causing edema, ischemia, and eventually

demyelination. Although the precise etiology of Bell's Palsy is not yet identified to date, recently, enveloped DNA virus Herpes Zoster virus has been identified as one of its possible etiologies. Some conditions like Cholesteatoma, Parotid gland tumors, and Herpes Zoster Oticus cause isolated facial palsy similar to Bell's Palsy. Diabetes, sarcoidosis, Lyme disease, HIV infection, Sjogren's syndrome, leprosy, polyarthritis nodosa, and amyloidosis can cause Bell's-like facial paralysis (lower motor neuron type), which can be differentiated from Bell's Palsy by its quick onset during several hours.

Bell's Palsy is characterized by complete ipsilateral paralysis of all muscles of the face, disappearance of face creases and nasolabial fold, inability to close the affected eye, drooping of corners of the mouth, as well as drooling of food and saliva from the involved side. Recovery in Bell's Palsy is variable, whereas the majority completely recover; however, some patients develop permanent defacing (4). Old age (1), uncontrolled hypertension (5), dysgeusia (6), and complete paralysis (7) are considered the worst prognostic factors. Bell's Palsy rarely involves both sides of face. In case of bilateral involvements, it is suggested alternate diagnoses like Lyme's disease, lymphoma, or sarcoidosis (8). Diagnosis of Bell's Palsy is purely clinical. However, electrodiagnostic testing, if performed within two weeks of the onset, gives prognostic information. Facial muscles have shown no electrical activity within the first three days of palsy, whereas electrical activity started to steadily decline from days 4 to 10. Complete recovery occurs in 90% of patients where electrical excitability is retained, whereas if excitability loses, complete recovery drops to just only 20% (1, 9).

The pharmacological therapy of Bell's Palsy has always been a point of debate as of its unknown etiology. The mainstay pharmacological treatment for Bell's Palsy is corticosteroids (1) and antivirals [based on the rationale of proposed pathogenesis that is either an inflammation (steroid responsive) or HSV1 infection (antiviral responsive)] (10). The present study was designed to evaluate the pharmacological effects of steroids in comparison to steroids with antiviral drugs for the treatment of Bell's Palsy. In other words, to compare the beneficial effects of prednisolone versus prednisolone + acyclovir on Bell's Palsy and to compare primary and secondary outcomes among both groups.

## 2. Methods

### 2.1. Patient Selection

Prior approval was sought from Institutional Review Board (IRB-DUHS) before the commencement of this study,

where all ethical aspects were evaluated. After suggested corrections by worthy IRB-DUHS; finally, ethical approval was granted. All patients with a confirmed diagnosis of Bell's Palsy aged 18 years or greater with either sex who presented either in medicine department, ENT, neurology department or physiotherapy and rehabilitation center of Civil Hospital Karachi within 4 days of symptoms of Bell's Palsy were enrolled for the study. Written informed consent was obtained from all participants after a proper explanation of anticipated benefits versus risk of the study. Patients with diabetes, Herpes Zoster, sarcoidosis, multiple sclerosis, systemic infection, suppurative otitis media, malignancy, and bleeding peptic ulcers were excluded from the study. Pregnant and breastfeeding patients were also excluded.

### 2.2. Study Protocol

#### 2.2.1. Diagnosis of Bell's Palsy

Bell's Palsy was diagnosed based on clinical presentations of acute facial nerve weakness or the onset of ipsilateral paralysis on one side of the face in less than 72 hours after exclusion of other likely causes of facial paralysis.

A total of 60 patients were enrolled and divided equally into two groups, where patients on prednisolone were labeled as group A (Control group), whereas on prednisolone + acyclovir were labeled as group B (Study group). Both groups were randomized where group A was given even numbers and group B was given odd numbers. All patients, recruiters, and outcome assessors were blind to medications given.

#### 2.2.2. Control Group

Patients in this group were given prednisolone with a standard dose of 1 mg/kg of bodyweight for 10 days and tapered for the next 5 days.

#### 2.2.3. Study Group

Patients in this group were given prednisolone with a standard dose of 1 mg/kg of bodyweight for 10 days and tapered for the next 5 days along with acyclovir 400 mg 4 times a day.

#### 2.2.4. Initial Visit and Follow-Up Protocol

All participants had initial visits where House Brackmann scores were calculated in both groups, and the control group started oral prednisolone 1 mg/kg for 10 days, whereas the study group started acyclovir 400 mg 4 times a day for 10 days along with tablet prednisolone. Patients were regularly observed till the study was completed. Patients were called up every week for 4 weeks and then finally, on 8th week where facial nerve paralysis recovery

were carefully evaluated by clinical examination by authors, and recovery was graded by House Brackmann grading scale. The secondary outcome measures were calculated by Health Utility Index Mark 3 and Derriford appearance scale 59 both on 4th and 8th weeks.

#### 2.2.5. Primary Outcome Measures

Primary outcome measure was facial nerve recovery, which is assessed by a grading system known as House Brackmann grading system

#### 2.2.6. House Brackmann Grading

It is a widely used, simply applicable, and well-validated grading system which, characterizes the functions of facial nerve paralysis. It is graded from 1 to 6 where score 1 is normal facial nerve function, and score 6 denotes complete paralysis. Grades 2 to 5 are based on facial nerve functions at rest or with effort (11, 12).

#### 2.2.7. Secondary Outcome Measures

Health-related quality of life and facial appearance were considered secondary outcomes and were assessed by Health Utilities Index Mark 3 and Derriford Appearance Scale 59, respectively.

The Health Utilities Index Mark 3: This questionnaire-based tool was used for the assessment of the quality related to health that utilized eight variables, including speech, hearing, vision, cognition, ambulation, emotion, dexterity, and pain. Where 5 or 6 points of severity were given for one dimension (13). Scoring system for this scale is based on preference, where responses are changed into a single score which ranges from -0.36 to 1.00, where score of 1 indicates full quality of health, negative score indicates the worst quality of life.

Derriford Appearance Scale 59: This is a questionnaire-based scale to determine facial appearance and consisted of 59 questions based on confidence and self-consciousness. This score comprises 8-266 points, where high score indicates worse severity and distress (14).

#### 2.3. Statistical Analysis

Both groups were analyzed on the principle of intention to treat, and comparisons were done in accordance with the study protocol. Data were collected by the two assigned researchers themselves to avoid person-to-person bias, and they were blinded to the pharmacological treatment given to the patients. All data were analyzed statistically with SPSS version 21.

Data were initially tested for interaction between both control and treatment groups. In case of insignificant results, the comparison of the primary outcome (complete

recovery is represented by grade 1 on the House-Brackmann scale) at 1 month and 2 months was done in both groups. A two-sided Fisher's exact test was used. Secondary outcome measures namely quality of life (Health Utility Index Mark-3), facial appearance (Derriford appearance scale 59) was analyzed and compared through scores between both control and experimental groups using student *t*-test or Mann-Whitney U test wherever required. For all statistically significant analysis P-value < 0.05 was considered significant.

### 3. Results

A total of 83 patients were referred for enrolment, but 23 patients were excluded as they were not fulfilling the relevant criteria, and the remaining 60 patients were finally enrolled and randomly divided into the control and study groups.

#### 3.1. Baseline Characteristics (Control Group)

Patients in the control group (given prednisolone) were mainly (56.6%) male, and the mean age of the patients was 31.1 years. Baseline scores of House Brackmann, Health utility index mark-3, and Derriford appearance scale were  $3.9 \pm 0.9$ ,  $0.97 \pm 0.13$ , and  $69 \pm 34$ , respectively. Moreover, 46.666% of the patients had initiated the treatment within 24 hours, while 40% had initiated the treatment within 24 to 48 hours, and only 13.333% of the patients had initiated the treatment between 48 hours to 72 hours (Table 1).

#### 3.2. Baseline Characteristic (Study Group)

The patients in the study group (given prednisolone + acyclovir) were mainly (60%) male, and the mean age of the patients was 39.1 years. Baseline scores of House Brackmann, Health utility index mark-3, and Derriford appearance scale were  $3.4 \pm 1.1$ ,  $0.82 \pm 0.11$ , and  $71 \pm 36$ , respectively. Also, 53.333% of the patients had initiated the treatment within 24 hours, while 36.333% had initiated the treatment within 24 to 48 hours, and only 10% of the patients had initiated treatment between 48 hours to 72 hours (Table 1).

#### 3.3. Primary Outcomes

The primary outcomes assessed as complete recovery from Bell's Palsy by Brackmann score of 1 at 4 weeks were found in 17/30 (57%) patients in the control group. However, at the end of week 8, 23/30 (77%) patients in the control group showed a complete recovery (score 1 on Brackmann scale) (Table 2). Complete recovery from Bell's Palsy was also shown in the experimental group (prednisolone

**Table 1.** Baseline Characteristics of Participants

Demographic Profile	Group A	Group B	Total
<b>Gender, No. (%)</b>			
Male	17 (56.6)	18	30
Female	13 (44.4)	12	30
<b>Age (y)</b>			
	31.1	39.9	
<b>House Brackmann score</b>			
	3.9 ± 0.9	3.4 ± 1.1	3.6 ± 1.13
<b>Health utility index mark</b>			
	0.97 ± 0.13	0.82 ± 0.11	0.85 ± 0.15
<b>Derriford appearance scale, score</b>			
	69 ± 34	71 ± 36	72.8 ± 32.4
<b>Time between symptoms onset and initiation of treatment, No. (%)</b>			
Within 24 hours	14 (46.666)	16 (53.3)	30 (50)
24 — ≤ 48 hours	12 (40)	11 (36.66)	23 (38)
> 48 — ≤ 72 hours	04 (13.333)	03 (10)	07 (11.6)

+ acyclovir) where at the end of 4th week, 25/30 (83%) patients showed a complete recovery (score 1 on Brackmann scale) and 27/30 (90%) ones at week 8 showed a complete recovery (score 1 on Brackmann scale) (Table 2). When complete recovery was compared between the two groups at week 4, it showed more a significant increase in the study group (prednisolone + acyclovir) (P = 0.047, Table 2). When compared at 8th week, a significantly higher recovery was observed in the study group (P = 0.02, Table 2).

### 3.4. Secondary Outcomes

The secondary outcomes were assessed as improvement in the quality of life and facial appearance from Bell's Palsy by Health utility index scale-3 and Derriford appearance scale 59, respectively. At 4th week, Health utility score was  $0.84 \pm 0.01$  in the control group (On prednisolone) with a facial appearance score of (Derriford appearance scale 59)  $61 \pm 28$  (Table 2). At 4th, the study group (on prednisolone+ acyclovir) showed  $0.88 \pm 0.12$  score on Health utility index scale-3 and  $46 \pm 26$  score on Derriford appearance scale. When compared secondary outcomes related to the quality of life (Health quality index scale-3) between both control and study groups, a significantly higher improvement was observed in the study group (P = 0.001, Table 2). When facial appearance, as a secondary outcome, was compared between the groups, a significantly higher improvement was observed in the study group (P = 0.005, Table 2). However, at the end of week 8, the secondary outcomes assessed by Health-related utility index score and Derriford appearance score were  $0.95 \pm 0.14$  and  $42 \pm 24$ , respectively. When health utility score and Derriford appearance were compared between both groups, a significantly higher improvement was observed in the study

group (prednisolone + acyclovir) (P = 0.001 and 0.016, respectively, Table 2).

### 4. Discussion

This clinical comparative study demonstrates the efficacy and benefits of the treatment for Bell's Palsy between two groups; one group received prednisolone, and the other group received prednisolone in combination with acyclovir. Most of the patients in both groups were males, and the mean ages of the patients were 31 and 39.1 years in the control and study groups, respectively. This male predominance and age distribution are in accordance with a previously published trial (15). Most of the patients in the control group (prednisolone) started the treatment within 24 hours, whereas the treatment started within 24 to 48 hours in 40% of the patients, and only 4% of the patients started the treatment between 48 to 72 hours. This duration of the commencement of the treatment was similar to a previously published study (15). Patients in the study group (prednisolone + acyclovir) also showed similar results where most of the patients started the treatment within 24 hours, which is again in accordance with a previous similar trial (15).

House Brackmann grading system for the assessment of facial nerve functions was used in this study because of its validity and easy application. comparison to other alternative scales like Sunnybrook and Sydney facial grading (16). The baseline score of facial nerve function was  $3.6 \pm 1.13$  on House Brackmann scale in this study. A recent large study has also shown similar baseline House Brackmann scores ( $3.5 \pm 1.2$ ) to our study (15). Another previous study (17) has also shown experience of 30 cases of Bell's Palsy and showed complete recovery of 87%; however, the exact value

**Table 2.** Primary and Secondary Outcomes at Weeks 4 and 8

Variables	Control Group Prednisolone (30)	Study Group (30)	P-Value	Odds Ratio (CI)
<b>Primary outcome</b>				
House Brackman scale (Stage 1)				
At week 4	17/30 (57%)	25/30 (83%)	0.047	0.260 (0.07-0.87)
At week 8	23/30 (77%)	27/30 (90%)	0.021	0.14 (0.028-0.724)
<b>Secondary outcome</b>				
Derriford appearance scale 59 (Score)				
At week 4	61 ± 28	46 ± 26	0.005	
At week 8	55 ± 30	42 ± 24	0.016	
Health utility index mark-3 scale				
At week 4	0.84 ± 0.01	0.88 ± 0.12	0.001	
At week 8	0.87 ± 0.02	0.95 ± 0.14	0.000	

of House Brackmann was not given.

This study has shown the complete recovery in the prednisolone group at weeks 4, and 8 was 57 and 77%, which is in accordance with a previously published study (17), where complete recovery was observed in 87% of the patients. The study group (prednisolone + acyclovir) in this study has shown 83% to 90% of complete recovery, which is statistically significant compared with the control group. A previous trial has confirmed complete recovery (57% to 94.5%) of Bell's Palsy at 3 and 8 months, respectively (15). Two earlier studies (18, 19) have also shown similar results as observed in our study. A large meta-analysis was inconsistent with this study, where the addition of acyclovir with prednisolone was not proven beneficial (20). Another recent trial also has in contrast to the present study where investigators did not find any improvement with the addition of antiviral valaciclovir with steroids in Bell's recovery (21). A recent study (22) has shown similar results where the addition of acyclovir to prednisolone has been found to be superior in the treatment of Bell's Palsy where patients had a 76.2% recovery, while prednisolone given alone had a 57.1% recovery. Kawaguchi et al. (23) showed an improved recovery of Bell's Palsy in patients with a combined use of prednisolone and valaciclovir than prednisolone alone. Another study supported this study where the unfavorable risk of recovery of Bell's Palsy was less with glucocorticoid and antiviral versus prednisolone alone (24). Similar benefits of recovery were reported by previous studies (25, 26) where treatment with antiviral and prednisolone was found superior to prednisolone alone.

The present study also assessed the secondary outcome of Bell's Palsy in terms of quality of life determined by Health utility index-3 and Derriford facial appearance scale-59 between both groups. This study has shown more

improvement in terms of quality of life and facial appearance in the prednisolone and acyclovir group in comparison to the prednisolone group alone. A previous trial (15) was inconsistent with our study where no benefit was observed in secondary outcomes in Bell's Palsy in combination with prednisolone and acyclovir as opposed to prednisolone alone. There are certain limitations to this comparative study in which small sample size and steroids were not head to head compared for recovery of Bell's Palsy as steroids have to be added in the study group to avoid ethical issues because steroids are gold standard for Bell's Palsy treatment.

**4.1. Conclusions**

This study concludes that the combination of prednisolone with acyclovir is superior to prednisolone alone in the pharmacological management of Bell's Palsy. The combination treatment has shown improvement in both recovery and quality of life.

**Footnotes**

**Authors' Contribution:** AT, IHN conceived, designed, performed statistical analysis, and edited the manuscript. MGB, MU, and AT collected data and drafted the manuscript. AT reviewed and approved the final manuscript.

**Conflict of Interests:** The authors declare no conflicts of interest.

**Data Reproducibility:** The data presented in this study are openly available in one of the repositories or will be available on request from the corresponding author by this journal representative at any time during submission or after publication.

**Ethical Approval:** Prior approval was sought from Institutional Review Board (IRB-DUHS) before the commencement of this study where all ethical aspects were evaluated. After suggested corrections by worthy IRB-DUHS; finally, ethical approval was granted.

**Funding/Support:** None.

**Informed Consent:** Informed consent was obtained.

## References

- Gilden DH. Clinical practice. Bell's Palsy. *N Engl J Med*. 2004;**351**(13):1323–31. doi: [10.1056/NEJMcP041120](https://doi.org/10.1056/NEJMcP041120). [PubMed: [15385659](https://pubmed.ncbi.nlm.nih.gov/15385659/)].
- Morris AM, Deeks SL, Hill MD, Midroni G, Goldstein WC, Mazzulli T, et al. Annualized incidence and spectrum of illness from an outbreak investigation of Bell's palsy. *Neuroepidemiology*. 2002;**21**(5):255–61. doi: [10.1159/000065645](https://doi.org/10.1159/000065645). [PubMed: [12207155](https://pubmed.ncbi.nlm.nih.gov/12207155/)].
- Peitersen E. Bell's Palsy: The spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. *Acta Oto-Laryngologica*. 2002;**122**(7):4–30.
- Linder T, Bossart W, Bodmer D. Bell's palsy and Herpes simplex virus: fact or mystery? *Otol Neurotol*. 2005;**26**(1):109–13. doi: [10.1097/00129492-200501000-00020](https://doi.org/10.1097/00129492-200501000-00020). [PubMed: [15699730](https://pubmed.ncbi.nlm.nih.gov/15699730/)].
- Stjernquist-Desatnik A, Skoog E, Aurelius E. Detection of herpes simplex and varicella-zoster viruses in patients with Bell's palsy by the polymerase chain reaction technique. *Ann Otol Rhinol Laryngol*. 2006;**115**(4):306–11. doi: [10.1177/000348940611500410](https://doi.org/10.1177/000348940611500410). [PubMed: [16676828](https://pubmed.ncbi.nlm.nih.gov/16676828/)].
- Makeham TP, Croxson GR, Coulson S. Infective causes of facial nerve paralysis. *Otol Neurotol*. 2007;**28**(1):100–3. doi: [10.1097/01.mao.0000232009.01116.3f](https://doi.org/10.1097/01.mao.0000232009.01116.3f). [PubMed: [17031324](https://pubmed.ncbi.nlm.nih.gov/17031324/)].
- Redaelli de Zinis LO, Gamba P, Balzanelli C. Acute otitis media and facial nerve paralysis in adults. *Otol Neurotol*. 2003;**24**(1):113–7. doi: [10.1097/00129492-200301000-00022](https://doi.org/10.1097/00129492-200301000-00022). [PubMed: [12544039](https://pubmed.ncbi.nlm.nih.gov/12544039/)].
- Rajaguru S, Havlichek D, Khalife W, Kalra A. A 20-year-old man with fever, headache, and neck stiffness. Neuroborreliosis with tick-borne relapsing fever. *Clin Infect Dis*. 2011;**52**(2):218. 271-2. doi: [10.1093/cid/ciq120](https://doi.org/10.1093/cid/ciq120). [PubMed: [21288847](https://pubmed.ncbi.nlm.nih.gov/21288847/)].
- Tran TN, Ray GT, Horberg MA, Yawn BP, Castillo AL, Saddier P, et al. Complications of herpes zoster in cancer patients. *Scand J Infect Dis*. 2014;**46**(7):528–32. doi: [10.3109/00365548.2014.901554](https://doi.org/10.3109/00365548.2014.901554). [PubMed: [24796470](https://pubmed.ncbi.nlm.nih.gov/24796470/)].
- Holland NJ, Weiner GM. Recent developments in Bell's palsy. *BMJ*. 2004;**329**(7465):553–7. doi: [10.1136/bmj.329.7465.553](https://doi.org/10.1136/bmj.329.7465.553). [PubMed: [15345630](https://pubmed.ncbi.nlm.nih.gov/15345630/)]. [PubMed Central: [PMC516110](https://pubmed.ncbi.nlm.nih.gov/PMC516110/)].
- Gronseth GS, Paduga R, American Academy of N. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2012;**79**(22):2209–13. doi: [10.1212/WNL.0b013e318275978c](https://doi.org/10.1212/WNL.0b013e318275978c). [PubMed: [23136264](https://pubmed.ncbi.nlm.nih.gov/23136264/)].
- House JW, Brackmann DE. Facial nerve grading system. *Otolaryngol Head Neck Surg*. 1985;**93**(2):146–7. doi: [10.1177/019459988509300202](https://doi.org/10.1177/019459988509300202). [PubMed: [3921901](https://pubmed.ncbi.nlm.nih.gov/3921901/)].
- Kim DW, Egan KK. *Facial Nerve Paralysis*. Citeseer; 2007.
- Horsman J, Furlong W, Feeny D, Torrance G. The health utilities index (HUI): concepts, measurement properties and applications. *Health Qual Life Outcomes*. 2003;**1**:54. doi: [10.1186/1477-7525-1-54](https://doi.org/10.1186/1477-7525-1-54). [PubMed: [14613568](https://pubmed.ncbi.nlm.nih.gov/14613568/)]. [PubMed Central: [PMC293474](https://pubmed.ncbi.nlm.nih.gov/PMC293474/)].
- Harris DL, Carr AT. The derrirod appearance scale (DAS59): A new psychometric scale for the evaluation of patients with disfigurements and aesthetic problems of appearance. *Br J Plast Surg*. 2001;**54**(3):216–22. doi: [10.1054/bjps.2001.3559](https://doi.org/10.1054/bjps.2001.3559). [PubMed: [11254413](https://pubmed.ncbi.nlm.nih.gov/11254413/)].
- Croxson G, May M, Mester SJ. Grading facial nerve function: House-Brackmann versus Burres-Fisch methods. *Am J Otol*. 1990;**11**(4):240–6. [PubMed: [2399941](https://pubmed.ncbi.nlm.nih.gov/2399941/)].
- Ross BG, Fradet G, Nedzelski JM. Development of a sensitive clinical facial grading system. *Otolaryngol Head Neck Surg*. 1996;**114**:380–6. doi: [10.1016/S0194-5998\(96\)70206-1](https://doi.org/10.1016/S0194-5998(96)70206-1).
- Priya R, Monga S, Malik J, P Sharma A, Shamim H, Rasool S, et al. Bell's palsy: Our experience and review of 30 cases. *Otolaryngol Head Neck Surg*. 2019;**4**(2). doi: [10.15761/ohns.1000202](https://doi.org/10.15761/ohns.1000202).
- Grogan PM, Gronseth GS. Practice parameter: Steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2001;**56**(7):830–6. doi: [10.1212/wnl.56.7.830](https://doi.org/10.1212/wnl.56.7.830). [PubMed: [11294918](https://pubmed.ncbi.nlm.nih.gov/11294918/)].
- Rowlands S, Hooper R, Hughes R, Burney P. The epidemiology and treatment of Bell's palsy in the UK. *Eur J Neurol*. 2002;**9**(1):63–7. doi: [10.1046/j.1468-1331.2002.00343.x](https://doi.org/10.1046/j.1468-1331.2002.00343.x). [PubMed: [11784378](https://pubmed.ncbi.nlm.nih.gov/11784378/)].
- Goudakos JK, Markou KD. Corticosteroids vs corticosteroids plus antiviral agents in the treatment of Bells Palsy: A systematic review and meta-analysis. *Arch Otolaryngol Head Neck Surg*. 2009;**135**(6):558–64. doi: [10.1001/archotol.125.12.1335](https://doi.org/10.1001/archotol.125.12.1335).
- Engstrom M, Berg T, Stjernquist-Desatnik A, Axelsson S, Pitkaranta A, Hultcrantz M, et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet Neurol*. 2008;**7**(11):993–1000. doi: [10.1016/S1474-4422\(08\)70221-7](https://doi.org/10.1016/S1474-4422(08)70221-7). [PubMed: [18849193](https://pubmed.ncbi.nlm.nih.gov/18849193/)].
- Kawaguchi K, Inamura H, Abe Y, Kosu H, Takashita E, Muraki Y, et al. Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. *Laryngoscope*. 2007;**117**(1):147–56. doi: [10.1097/01.mlg.0000248737.65607.9e](https://doi.org/10.1097/01.mlg.0000248737.65607.9e). [PubMed: [17202945](https://pubmed.ncbi.nlm.nih.gov/17202945/)].
- de Almeida JR, Al Khabori M, Guyatt GH, Witterick IJ, Lin VY, Nedzelski JM, et al. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. *JAMA*. 2009;**302**(9):985–93. doi: [10.1001/jama.2009.1243](https://doi.org/10.1001/jama.2009.1243). [PubMed: [19724046](https://pubmed.ncbi.nlm.nih.gov/19724046/)].
- Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F, Lockhart P. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). *Cochrane Database of Systematic Reviews*. John Wiley & Sons; 2009.
- Hato N, Yamada H, Kohno H, Matsumoto S, Honda N, Gyo K, et al. Valacyclovir and prednisolone treatment for Bell's Palsy. *Otol Neurotol*. 2007;**PAP**. doi: [10.1097/MAO.0b013e3180306371](https://doi.org/10.1097/MAO.0b013e3180306371).